Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United Sta…
$7.97+1.01%
报价 2026-11-06
市值
$409.2M
EV
$181.1M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -30.8%
$7.89$11.51
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| PRTAProthena Corporation plc | $409.2M | +1.0% | – | -208.6% | – | – | – | |
| ARVNArvinas, Inc. | $419.1M | -2.1% | -58.0% | 96.8% | 47.4x | 64.2x | – | |
| RLMDRelmada Therapeutics, Inc. | $416M | +3.4% | +300.0% | 0% | – | – | – | |
| ASMBAssembly Biosciences, Inc. | $415.8M | +2.1% | +57.1% | 72.9% | 54.5x | – | – | |
| CRMDCorMedix Inc. | $414.7M | +1.7% | +3.7% | 82.8% | 3.4x | 2.4x | 2.5x | |
| ALTAltimmune, Inc. | $404.6M | +5.6% | -100.0% | -36,387.8% | – | – | – | |
| TECXTectonic Therapeutic, Inc. | $403.5M | +6.3% | – | 0% | – | – | – | |
| NGNENeurogene Inc. | $400M | -1.3% | -44.4% | 0% | – | – | – | |
| EDITEditas Medicine, Inc. | $394.7M | +0.8% | -41.9% | 56.9% | – | – | – | |
| 同行中位数 | – | – | -41.9% | 28.4% | 47.4x | 33.3x | 2.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。